Precipio

Precipio to Effect 1-for-15 Reverse Stock Split

In Brief This Week: BioDirection, Quest Diagnostics, OncoCyte, and More

In Brief This Week: WHO, Cancer Genetics, Interpace Diagnostics, and More

In Brief This Week: Danaher, Natera, Chembio, and More

In Brief This Week: Precipio, OpGen, Genedrive, and Danaher

Lung Cancer Screening Study at UCMC to Utilize Precipio ICE-COLD PCR Tech

PerkinElmer, Precipio Collaborate On Liquid Biopsy Testing

Precipio Reports 140 Percent Jump in Preliminary Q3 Revenues

Precipio Gets Extension to Meet Nasdaq Listing Requirement

Precipio Posts Preliminary Q2 Revenue Growth of 213 Percent

Precipio Settles Lawsuit With Investment Group

Precipio Sued Over Transgenomic Securities Agreement

Precipio Completes Public Offering, Raises $2.7M

Precipio Diagnostics Prices $2.7M Direct Offering

In Brief This Week: Siemens Healthineers, Precipio Diagnostics, Transgenomic, Orig3n, and More

Transgenomic Shareholders Approve Merger With Precipio Dx

Transgenomic Closes Bridge Financing

LifeLabs Licenses Transgenomic Technology

Transgenomic, Precipio Diagnostics Ink Merger Agreement

Transgenomic Licenses Heart Rhythm Disorder Testing IP to LabCorp